Orientation of epitopes influences the immunogenicity of synthetic peptide dimers.

Eur J Immunol

MRC Tuberculosis and Related Infections Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London.

Published: December 1988

The immunogenicity of synthetic peptide dimers based on epitope sequences derived from the mycobacterial 65-kDa antigen and the foot and mouth disease virus (FMDV) VP1 protein was examined in inbred mice. The analysis was directed towards the potential helper role of a T cell stimulatory mycobacterial epitope (65-85) with respect to poorly immunogenic sites either from the same molecule (422-436) or from VP1 (141-160). The 65-85 repeat homodimer induced an antibody response in CBA/ca but not in C57BL/6 mice, both nonresponders to the 65-85 monomer, and amplified the antibody response in BALB/c, monomer-responder mice. Analysis of the immunogenicity of hybrid dimers in BALB/c mice showed that the orientation of peptides within the dimer is critical for the extent of the produced antibody response. Only the 422-436/65-85 but not the 65-85/422-436 induced antibodies binding to the 422-436 sequence which was nonimmunogenic when injected either as a monomer or dimer. Despite the striking difference in immunogenicity, both tested hybrid dimers reacted equally in the solid-phase immunoassay with antisera raised to 65-85-dimer or 422-436/65-85 peptides or with a monoclonal antibody to the 422-436 epitope. The described differences in antibody responsiveness also cannot be attributed merely to the extent of T cell stimulation since the proliferative responses were uniformly expressed for all relevant combinations of peptides. Antisera to 65-85 dimer and 422-436/65-85 hybrid also reacted with the native 65-kDa protein. Furthermore, the production of FMDV-neutralizing antibodies in response to the 141-160 (VP1-derived)/65-85 hybrid peptide in 141-160 nonresponder B10.D2 mice also confirmed the helper activity of the 65-85 epitope. Thus, combining heterologous peptides with the N-terminal of the mycobacterial 65-85 sequence may be generally applicable for the potentiation of peptide vaccines.

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.1830181222DOI Listing

Publication Analysis

Top Keywords

antibody response
12
immunogenicity synthetic
8
synthetic peptide
8
peptide dimers
8
mice analysis
8
hybrid dimers
8
65-85
6
mice
5
antibody
5
orientation epitopes
4

Similar Publications

P-cadherin, a crucial cell-cell adhesion protein which is overexpressed in numerous malignant cancers, is a popular target for drug delivery antibodies. However, molecular guidelines for engineering antibodies that can be internalized upon binding to P-cadherin are unknown. Here, we use a combination of biophysical, biochemical, and cell biological methods to demonstrate that trapping the P-cadherin extracellular region in an X-dimer adhesive conformation triggers cadherin endocytosis via an outside-in signaling mechanism.

View Article and Find Full Text PDF

Functional epitope mapping of cell surface glucose-regulated protein 94: A combinatorial approach for therapeutic targeting.

Int J Biol Macromol

January 2025

Department of Chemistry, Kookmin University, Seoul 02707, Republic of Korea; Department of Biopharmaceutical Chemistry, Kookmin University, Seoul 02707, Republic of Korea; Antibody Research Institute, Kookmin University, Seoul 02707, Republic of Korea. Electronic address:

Glucose-regulated protein 94 (GRP94) overexpression plays a critical role in tumor cell survival across various cancers. Previously, we developed K101.1, a fully human antibody targeting cell surface GRP94, which effectively inhibits tumor angiogenesis in colorectal cancer (CRC).

View Article and Find Full Text PDF

Background: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran.

Methods: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects.

View Article and Find Full Text PDF

Mitigation of ischemia/reperfusion injury via selenium nanoparticles: Suppression of STAT1 to inhibit cardiomyocyte oxidative stress and inflammation.

Biomaterials

January 2025

Chongqing Key Laboratory of Reproductive Health and Digital Medicine, Department of Laboratory Medicine, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 400044, People's Republic of China; College of Life Science and Laboratory Medicine, Kunming Medical University, Kunming, Yunnan, 650050, People's Republic of China. Electronic address:

Ischemia/reperfusion injury (I/RI) following myocardial infarction, a leading cause of global morbidity and mortality, is characterized by detrimental oxidative stress and inflammation. In response, we proposed an I/RI alleviation strategy using the intravenous injection of spherical selenium nanoparticles (SeNPs) synthesized by a template method. Single-cell sequencing revealed these proposed SeNPs exhibited exceptional antioxidant and anti-inflammatory properties, disrupting the STAT1-ROS cycle, therefore preserving mitochondrial respiration and inhibiting caspase-mediated cardiomyocyte apoptosis.

View Article and Find Full Text PDF

Background: Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing 'LALA' mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Methods: 292 patients with advanced non-squamous NSCLC were randomized 1:1 to receive 4 cycles of pemetrexed, platinum-based drug and either prolgolimab (3 mg/kg Q3W) or placebo followed by prolgolimab/placebo with pemetrexed until disease progression or toxicity (≤36 months).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!